Results 121 to 130 of about 385 (131)

Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM

Journal of the American College of Cardiology
Albree Tower-Rader, Michael Nassif, Pablo García-Pavía   +2 more
exaly  

Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Michael Nassif, Amy Wohltman, Steen H Poulsen   +2 more
exaly  

Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Journal of Cardiac Failure
Albree Tower-Rader, Ahmad Masri, Lisa Meng   +2 more
exaly  

SEQUOIA-HCM: Aficamten effects consistent across regions

Medicom Conference Report HFA 2025
openaire   +1 more source

Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of [ 14 C]aficamten following single oral dose administration to rats

Xenobiotica
exaly  

SEQUOIA-HCM: Aficamten safe and efficacious for HCM across the globe

Medicom Conference Report HFA 2025
openaire   +1 more source

SEQUOIA-HCM: Aficamten demonstrates clinical efficacy in obstructive HCM

Medicom Conference Report HFA 2024
openaire   +1 more source

Aficamten in Hypertrophic Cardiomyopathy: Roots and Branches of SEQUOIA.

Journal of the American College of Cardiology
openaire   +1 more source

AFICAMTEN DOSAGE REGIMENS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

MALIK FADY, KUPFER STUART, HEITNER STEPHEN B, ROBERTSON LAURA ANN, MENG LIXIN, OSMUKHINA ANNA, WOHLTMAN QI   +6 more
openaire   +1 more source

Echocardiographic Changes With Aficamten: A Pixel Is Worth 1,024 Bits.

Journal of the American College of Cardiology
openaire   +1 more source